Welcome to our dedicated page for Stagezero Life news (Ticker: SZLSF), a resource for investors and traders seeking the latest updates and insights on Stagezero Life stock.
StageZero Life Sciences (SZLSF) is a healthcare company revolutionizing cancer detection with its proprietary liquid biopsy multi-cancer diagnostic test, Aristotle®. By screening for multiple cancers from a single blood sample, Aristotle® offers high sensitivity and specificity for each cancer type. The company also provides oncologist-led treatment protocols, such as the COC Protocol, to target metabolic cancer pathways for improved patient outcomes. With a focus on early detection and unique telehealth programs like AVRT, StageZero is dedicated to advancing cancer care. Through its clinical laboratory in Richmond, Virginia, StageZero continues to innovate in the fight against cancer.
StageZero Life Sciences, an integrated healthcare company specializing in mRNA gene expression multi-cancer diagnostics, announced updates on its 2023 financial filings under a Failure to File Cease Trade Order (FFCTO). The company had previously delayed filing due to insufficient funds to pay auditors. The Ontario Securities Commission granted StageZero until July 8, 2024, to file its year-end financials for automatic revocation of the FFCTO. Although the audit and associated documents, including MD&A and AIF, are nearly complete, final payment to auditors is still pending. The company is also compliant with its Q1 2024 financials. The FFCTO bans trading of StageZero's securities in Canada until the filing is completed and the FFCTO is revoked.
StageZero Life Sciences has provided an update on the filing of its full-year 2023 financials amid a Failure to File Cease Trade Order (FFCTO) imposed by the Ontario Securities Commission (OSC). The company cited financial constraints as a reason for the delayed audit in April. With the OSC's deadline fast approaching on July 8, 2024, StageZero has nearly completed the audit and is in the process of settling auditor fees. The FFCTO restricts any trading of the company's securities in Canada until the financial documents are filed and the order is revoked.
StageZero Life Sciences announced that it remains under a Failure to File Cease Trade Order (FFCTO) due to a delay in filing its 2023 year-end financials. The company cited insufficient financial resources to pay auditors as the cause of the delay. The Ontario Securities Commission has granted StageZero 90 days to rectify the situation, giving them a deadline of July 3, 2024. Despite efforts to file ahead of the deadline, StageZero will not meet the originally referenced May 31, 2024, filing date. The FFCTO prohibits any trading of the company's securities in Canada until the filings are completed and the order is revoked. StageZero confirms no other undisclosed material information about its affairs.
StageZero Life Sciences (TSX:SZLS) announced its Q1 2024 financial results and provided an operational update. The company reported revenue of $0.523 million for cancer testing and treatment, a decrease from $0.778 million in Q1 2023. Net loss reduced to $0.386 million from $1.812 million in the same period last year. Key developments include advanced discussions with multiple partners in the US and Canada, reorganization of the Richmond lab, and formalized business development in Europe. Upcoming catalysts for 2024 include new partnerships focused on Aristotle, Care Oncology US expansion, and multiple cancer studies. Gross profit was $0.302 million with a gross margin of 58%.
FAQ
What is the current stock price of Stagezero Life (SZLSF)?
What is the market cap of Stagezero Life (SZLSF)?
What is Aristotle®?
What is the COC Protocol?
What is AVRT?
Where is StageZero's clinical laboratory located?
What sets StageZero apart in cancer care?
